0K30 Stock Overview

A clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. More details

0K30 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

Rewards

Earnings have grown 6% per year over the past 5 years

Risk Analysis

Has less than 1 year of cash runway

Shareholders have been substantially diluted in the past year

Shares are highly illiquid

Does not have a meaningful market cap (€10M)

+ 1 more risk

My Notes

Capture your thoughts, links and company narrative

TFF Pharmaceuticals, Inc. Competitors

Biofrontera

XTRA:B8FK

€13.1m

MPH Health Care

DB:93M1

€94.2m

SynBiotic

DUSE:SBX

€22.0m

Redx Pharma

DB:0RX

€65.0m

Price History & Performance

Summary of share price highs, lows and changes for TFF Pharmaceuticals
Historical stock prices
Current Share Price	€2.18
52 Week High	€8.00
52 Week Low	€1.42
Beta	1.06
1 Month Change	0%
3 Month Change	22.47%
1 Year Change	-66.56%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-67.01%

Recent updates

Shareholder Returns

	0K30	DE Pharmaceuticals	DE Market
7D	0%	1.7%	0.3%
1Y	-66.6%	-16.3%	6.9%

Return vs Industry: 0K30 underperformed the German Pharmaceuticals industry which returned -16.3% over the past year.

Return vs Market: 0K30 underperformed the German Market which returned 7.2% over the past year.

Price Volatility

Is 0K30's price volatile compared to industry and market?
0K30 volatility
0K30 Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	5.5%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	11.8%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: 0K30's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine 0K30's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2018	19	Craig Jalbert	tffpharma.com

TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company’s drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment and prophylaxis of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection.

TFF Pharmaceuticals, Inc. Fundamentals Summary

How do TFF Pharmaceuticals's earnings and revenue compare to its market cap?
0K30 fundamental statistics
Market cap	€9.69m
Earnings (TTM)	-€17.81m
Revenue (TTM)	€1.12m

8.7x

P/S Ratio

-0.5x

P/E Ratio

Is 0K30 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0K30 income statement (TTM)
Revenue	US$1.16m
Cost of Revenue	US$10.70m
Gross Profit	-US$9.54m
Other Expenses	US$8.98m
Earnings	-US$18.52m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-4.17
Gross Margin	-821.41%
Net Profit Margin	-1,595.04%
Debt/Equity Ratio	0%

How did 0K30 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/31 17:22
End of Day Share Price	2024/10/31 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

TFF Pharmaceuticals, Inc. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Mayank Mamtani	B. Riley Securities, Inc.
Raghuram Selvaraju	H.C. Wainwright & Co.
Jason McCarthy	Maxim Group